Suppr超能文献

用于治疗急性感染性腹泻的益生菌

Probiotics for treating acute infectious diarrhoea.

作者信息

Allen Stephen J, Martinez Elizabeth G, Gregorio Germana V, Dans Leonila F

机构信息

School of Medicine, Swansea University, Room 314, The Grove Building, Singleton Park, Swansea, West Glamorgan, UK, SA2 8PP.

出版信息

Cochrane Database Syst Rev. 2010 Nov 10;2010(11):CD003048. doi: 10.1002/14651858.CD003048.pub3.

Abstract

BACKGROUND

Probiotics may offer a safe intervention in acute infectious diarrhoea to reduce the duration and severity of the illness.

OBJECTIVES

To assess the effects of probiotics in proven or presumed acute infectious diarrhoea.

SEARCH STRATEGY

We searched the Cochrane Infectious Diseases Group's trials register (July 2010), the Cochrane Controlled Trials Register (The Cochrane Library Issue 2, 2010), MEDLINE (1966 to July 2010), EMBASE (1988 to July 2010), and reference lists from studies and reviews. We also contacted organizations and individuals working in the field, and pharmaceutical companies manufacturing probiotic agents.

SELECTION CRITERIA

Randomized and quasi-randomized controlled trials comparing a specified probiotic agent with a placebo or no probiotic in people with acute diarrhoea that is proven or presumed to be caused by an infectious agent.

DATA COLLECTION AND ANALYSIS

Two reviewers independently assessed the methodological quality of the trial and extracted data. Primary outcomes were the mean duration of diarrhoea, stool frequency on day 2 after intervention and ongoing diarrhoea on day 4. A random-effects model was used.

MAIN RESULTS

Sixty-three studies met the inclusion criteria with a total of 8014 participants. Of these, 56 trials recruited infants and young children. The trials varied in the definition used for acute diarrhoea and the end of the diarrhoeal illness, as well as in the risk of bias. The trials were undertaken in a wide range of different settings and also varied greatly in organisms tested, dosage, and participants' characteristics. No adverse events were attributed to the probiotic intervention.Probiotics reduced the duration of diarrhoea, although the size of the effect varied considerably between studies.The average of the effect was significant for mean duration of diarrhoea (mean difference 24.76 hours; 95% confidence interval 15.9 to 33.6 hours; n=4555, trials=35) diarrhoea lasting ≥4 days (risk ratio 0.41; 0.32 to 0.53; n=2853, trials=29) and stool frequency on day 2 (mean difference 0.80; 0.45 to 1.14; n=2751, trials=20).The differences in effect size between studies was not explained by study quality, probiotic strain, the number of different strains, the viability of the organisms, dosage of organisms, the causes of diarrhoea, or the severity of the diarrhoea, or whether the studies were done in developed or developing countries.

AUTHORS' CONCLUSIONS: Used alongside rehydration therapy, probiotics appear to be safe and have clear beneficial effects in shortening the duration and reducing stool frequency in acute infectious diarrhoea. However, more research is needed to guide the use of particular probiotic regimens in specific patient groups.

摘要

背景

益生菌可能为急性感染性腹泻提供一种安全的干预措施,以缩短病程并减轻病情严重程度。

目的

评估益生菌对确诊或疑似急性感染性腹泻的疗效。

检索策略

我们检索了Cochrane传染病组试验注册库(2010年7月)、Cochrane对照试验注册库(《Cochrane图书馆》2010年第2期)、MEDLINE(1966年至2010年7月)、EMBASE(1988年至2010年7月),以及研究和综述的参考文献列表。我们还联系了该领域的组织和个人,以及生产益生菌制剂的制药公司。

入选标准

将特定益生菌制剂与安慰剂或无益生菌在确诊或疑似由感染性病原体引起的急性腹泻患者中进行比较的随机和半随机对照试验。

数据收集与分析

两名评价员独立评估试验的方法学质量并提取数据。主要结局为腹泻的平均持续时间、干预后第2天的排便频率以及第4天仍存在的腹泻情况。采用随机效应模型。

主要结果

63项研究符合纳入标准,共有8014名参与者。其中,56项试验招募了婴幼儿。这些试验在急性腹泻和腹泻疾病结束的定义、偏倚风险方面存在差异。试验在广泛的不同环境中进行,在测试的微生物、剂量和参与者特征方面也有很大差异。未发现不良事件归因于益生菌干预。益生菌可缩短腹泻持续时间,尽管不同研究之间效果大小差异很大。腹泻平均持续时间的平均效应显著(平均差24.76小时;95%置信区间15.9至33.6小时;n = 4555,试验 = 35),腹泻持续≥4天(风险比0.41;0.32至0.53;n = 2853,试验 = 29)以及第2天的排便频率(平均差0.80;0.45至1.14;n = 2751,试验 = 20)。研究之间效应大小的差异无法通过研究质量、益生菌菌株、不同菌株数量、微生物活力、微生物剂量、腹泻原因、腹泻严重程度,或研究是在发达国家还是发展中国家进行来解释。

作者结论

与补液疗法同时使用时,益生菌似乎是安全的,并在缩短急性感染性腹泻病程和减少排便频率方面具有明显的有益效果。然而,需要更多研究来指导特定患者群体中特定益生菌方案的使用。

相似文献

1
Probiotics for treating acute infectious diarrhoea.
Cochrane Database Syst Rev. 2010 Nov 10;2010(11):CD003048. doi: 10.1002/14651858.CD003048.pub3.
2
Probiotics for treating infectious diarrhoea.
Cochrane Database Syst Rev. 2004(2):CD003048. doi: 10.1002/14651858.CD003048.pub2.
3
Probiotics for the prevention of pediatric antibiotic-associated diarrhea.
Cochrane Database Syst Rev. 2011 Nov 9(11):CD004827. doi: 10.1002/14651858.CD004827.pub3.
4
Dietary interventions for recurrent abdominal pain in childhood.
Cochrane Database Syst Rev. 2017 Mar 23;3(3):CD010972. doi: 10.1002/14651858.CD010972.pub2.
5
Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children.
Cochrane Database Syst Rev. 2017 Dec 19;12(12):CD006095. doi: 10.1002/14651858.CD006095.pub4.
6
Probiotics for management of functional abdominal pain disorders in children.
Cochrane Database Syst Rev. 2023 Feb 17;2(2):CD012849. doi: 10.1002/14651858.CD012849.pub2.
7
Probiotics in infants for prevention of allergic disease.
Cochrane Database Syst Rev. 2025 Jun 13;6(6):CD006475. doi: 10.1002/14651858.CD006475.pub3.
8
Antiviral agents for infectious mononucleosis (glandular fever).
Cochrane Database Syst Rev. 2016 Dec 8;12(12):CD011487. doi: 10.1002/14651858.CD011487.pub2.
9
Polymer-based oral rehydration solution for treating acute watery diarrhoea.
Cochrane Database Syst Rev. 2016 Dec 13;12(12):CD006519. doi: 10.1002/14651858.CD006519.pub3.
10
Smectite for acute infectious diarrhoea in children.
Cochrane Database Syst Rev. 2018 Apr 25;4(4):CD011526. doi: 10.1002/14651858.CD011526.pub2.

引用本文的文献

2
Microbiome, dysbiosis and use of probiotics in various diseases.
World J Virol. 2025 Jun 25;14(2):99574. doi: 10.5501/wjv.v14.i2.99574.
3
Value of Probiotics on Outcome in Patients Following Liver Surgery: A Systematic Review and Meta-Analysis.
Medicina (Kaunas). 2025 Jun 10;61(6):1068. doi: 10.3390/medicina61061068.
4
Gut Microbial Signatures Associated with Cryptosporidiosis: A Case Series.
Microorganisms. 2025 Feb 5;13(2):342. doi: 10.3390/microorganisms13020342.
6
LRa05 in the treatment of acute diarrhea in children: a randomized controlled trial.
Front Nutr. 2024 Nov 15;11:1479186. doi: 10.3389/fnut.2024.1479186. eCollection 2024.
7
Recent advances in bacteria-based platforms for inflammatory bowel diseases treatment.
Exploration (Beijing). 2024 Mar 5;4(5):20230142. doi: 10.1002/EXP.20230142. eCollection 2024 Oct.
9
Treatment Effects in Randomized and Nonrandomized Studies of Pharmacological Interventions: A Meta-Analysis.
JAMA Netw Open. 2024 Sep 3;7(9):e2436230. doi: 10.1001/jamanetworkopen.2024.36230.

本文引用的文献

2
Efficacy of Lactobacillus GG in aboriginal children with acute diarrhoeal disease: a randomised clinical trial.
J Pediatr Gastroenterol Nutr. 2010 Jun;50(6):619-24. doi: 10.1097/MPG.0b013e3181bbf53d.
3
[A multicentric study of a lactose free formula supplemented with Saccharomyces boulardii in children with acute diarrhea].
Arch Pediatr. 2010 May;17(5):459-65. doi: 10.1016/j.arcped.2010.02.004. Epub 2010 Mar 16.
6
Probiotics have clinical, microbiologic, and immunologic efficacy in acute infectious diarrhea.
Pediatr Infect Dis J. 2010 Feb;29(2):135-8. doi: 10.1097/inf.0b013e3181b530bf.
10
Saccharomyces boulardii for treating acute gastroenteritis in children: updated meta-analysis of randomized controlled trials.
Aliment Pharmacol Ther. 2009 Nov 1;30(9):960-1. doi: 10.1111/j.1365-2036.2009.04113.x.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验